))
#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) – efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape
Manage episode 444877276 series 3507376
Indhold leveret af Peter Attia. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Peter Attia eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
"If you're taking these drugs, really, really pay attention to your protein consumption and your resistance training. . .that's obviously going to be an important part of being on the right side of that body composition curve.” — Peter Attia
The post #320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) – efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape appeared first on Peter Attia.
35 episoder
Del
